The purpose of this study was to identify determinants of sudden death among clinical information in combination with cardiac fatty acid metabolism for better risk-stratification of haemodialysis patients.
Introduction
Impaired kidney function and advanced chronic kidney disease (CKD) significantly accelerate cardiovascular atherosclerosis, left ventricular hypertrophy, and cardiac dysfunction, leading to poor long-term outcomes. 1, 2 Patients with end-stage CKD have high cardiovascular mortality and sudden death risks with an annual event rate 5-30-times greater than that in the general population. 3 -5 Sudden death is the major mode of death in haemodialysis patients, contributing to nearly one-fourth of all-cause mortality and 50% or more of cardiovascular mortality. 6 Although the mechanisms are multifactorial and prevention of sudden death is an important clinical challenge, cardiovascular complications and cardiac mortality risk have not been sufficiently evaluated in these patients. This is partially because of infrequent consultation with a cardiologist and because of limited use of contrast medium in patients with advanced CKD. Although there is no single gold standard method at present, an optimal approach for predicting sudden death is needed for establishing a prophylactic management strategy against lethal outcomes in end-stage CKD or haemodialysis patients.
One of the new promising approaches is cardiac fatty acid metabolism imaging with a radiolabelled long-chain fatty acid analogue, 123 I-beta-methyl iodophenyl-pentadecanoic acid (BMIPP). 7, 8 A recent multicentre prospective investigation, the B-SAFE (BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients) study, 9, 10 demonstrated that, together with age and prior history of heart failure, impaired myocardial fatty acid metabolism assessed by 123 I-BMIPP is closely related to cardiac death in haemodialysis patients. Because of no enrolment of patients with definitive cardiac diseases or symptoms requiring medical treatment, 10 the B-SAFE results strongly suggest that cardiac BMIPP imaging can identify subclinical coronary artery disease responsible for future cardiac events. The aim of this B-SAFE sub-study was to more specifically identify determinants of sudden death among clinical information, haemodynamic data during haemodialysis, and cardiac fatty acid metabolism for better non-invasive risk-stratification of haemodialysis patients at an increased risk for sudden death.
Methods

Study design
The design of the B-SAFE study had been described before the study started. 10 Briefly, 683 patients undergoing haemodialysis who had one or more cardiovascular risk factors were registered between 1 July 2006 and 30 November 2007 at 48 hospitals in Japan. Cardiovascular risk factors were defined as follows: hypertension, diabetes mellitus, hypercholesterolaemia, peripheral artery disease, smoking habit, family history of juvenile coronary artery disease, history of ischaemic stroke, history of heart failure within 3 months of starting haemodialysis therapy and dialysis hypotension. Patients who had the following diseases or conditions were excluded from registration to the B-SAFE study: peritoneal dialysis, severe valvular disorders requiring treatment, diagnosis of dilated cardiomyopathy or hypertrophic cardiomyopathy before starting haemodialysis, and established the diagnosis of coronary artery disease including a history of coronary revascularization and prior myocardial infarction. Based on the Declaration of Helsinki, all patients provided written informed consent to participate in all study protocols before enrollment. All data recorded for this study were collected under strict protection of individual intelligence and analysed at the Translational Research Informatics Data Center (Kobe, Japan) independently of any medical centres or medical staff participating in this study. Among the 683 patients, 677 patients were finally enrolled for this prospective study and were followed up until 30 November 2010 or death for 3 years.
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Primary endpoint and sudden death
Although this sub-study focused on sudden death, the primary endpoints of the B-SAFE study consisted of both cardiac death due to determined cardiac origins and sudden death without definitive cause of death. Sudden death of unknown cause was defined as unexpected death within 24 h in which no definitive cause of death was determined clinically. Cardiac death was defined as death caused by heart failure, acute myocardial infarction, lethal ventricular arrhythmias, or other definitive cardiac disorders responsible for lethal outcomes. Physicians at each medical centre diagnosed cardiac death or sudden death with unknown origin and then finally B-SAFE steering committee members blinded to the imaging data confirmed the diagnosis.
5
123I-BMIPP imaging and data analysis
Myocardial BMIPP single emission computed tomography (SPECT) was performed on a mid-week non-dialysis day with an i.v. injection of 111-148 MBq of 123 I-BMIPP at rest. SPECT data were obtained using a standard camera and collimator 10 -30 min later and then a SPECT image was reconstructed. Based on the recommendation of the Cardiac Imaging Committee of the American Heart Association and the American Society of Nuclear Cardiology, 10,11 the left ventricular myocardium was divided into 17 segments and then BMIPP uptake was semi-quantitatively analysed using a 5-point visual scoring system (0, normal; 4, absent). All the SPECT images from the 677 patients were evaluated using the 5-point, 17-segement model by three independent teams consisting of two nuclear cardiology experts blinded to any clinical data except for gender information. 9 The abnormality of cardiac BMIPP SPECT images was expressed as a BMIPP score by summation of 17-segment scores.
Statistical analysis
Continuous and categorical variables are shown as means + standard deviation and as frequencies and percentage (%), respectively. To compare data between two groups, the Wilcoxon rank-sum test for continuous variables and the x 2 test for categorical variables were used.
Sudden death-free rates were calculated by the Kaplan-Meier method, and the log-rank test was used to compare the rates in the groups. Optimal cut-off values for C-reactive protein (CRP) and BMIPP score were determined when log-rank test statistics was maximal. For calculation of the hazard ratio (HR), the 95% confidence intervals (CIs) and P-values of the Wald test, the Cox proportional hazards model were used. Potential predictive factors for sudden death were selected for sudden death by significance of tests in univariate Cox regression analysis. Predictive factors were selected from potential predictive factors by a backwardselection method in multivariate Cox regression analysis. In addition, to construct clinical useful predictive tools, predictive performance of a combination of potential predictive categorical variables was investigated. Furthermore, to evaluate the predictive ability of predictors for time to sudden death, receiver-operating characteristic (ROC) analysis using area under the curve (AUC) was performed. Statistical significance was defined as P , 0.05. All data were statistically analysed using SAS version 9.1 (SAS Institute, Inc., Cary, NC, USA) and R version 3.1.2 software (R Foundation for Statistical Computing, Austria).
Results
Sudden death
During a median follow-up interval of 1152 days, 20 sudden deaths out of 125 (18.5%) lethal events in 677 haemodialysis patients were documented without a definitive determination of cause, accounting for 16% of all-cause mortality and 30% of cardiovascular mortality. Twenty-six patients (3.8%) died of cardiac events due to acute myocardial infarction (10 patients), congestive heart failure (13 patients), arrhythmias (2 patients), and valvular heart disease (1 patient), but none of the remaining 631 patients were lost for a 3-year follow-up interval. 5 This study included six patients undergoing pacemaker implantation who had no lethal cardiac event during a 3-year follow-up interval, but no patient undergoing implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT) was enrolled.
Comparison between the groups with and without sudden death events Table 1 shows the comparison of baseline characteristics and coronary risks between the 20 patients with sudden death events and the remaining 657 patients without sudden death events. There was no significant difference in any of the variables between the two groups.
The optimal cut-off values for prediction of sudden death were determined to be 2.38 mg/dL for CRP and 16 for BMIPP score, both of which had maximal log-rank statistics ( Figure 1 ). Table 2 shows that the group with sudden death events had more frequently increased CRP of more than 2.38 mg/dL than did the group without sudden death events (30.0 vs. 6.6%, P ¼ 0.005, respectively) and that there was no significant difference in other laboratory or haemodynamic variables, including left ventricular ejection fraction (LVEF). The sudden death group more frequently had abnormal Q-wave, greater BMIPP score, and the proportion of the patients with the BMIPP score .16 than did the non-sudden death group: 21.4 vs. 1.4%, P ¼ 0.002; 9.3 + 9.7 vs. 3.1 + 5.1, P , 0.001; 50.0 vs. 15.4%, P , 0.001, respectively ( Table 3) .
Prediction models by univariate and multivariate Cox regression analyses
Univariate Cox regression analysis using the variables listed in Tables 1-3 revealed predictive factors for sudden death as follows ( Table 5) . Multivariate Cox regression analysis using abnormal Q-wave and continuous and categorical variables of BMIPP score and CRP showed that BMIPP and BMIPP score .16 were significant (P , 0.001 to ,0.028) and that CRP and CRP .2.38 mg/mL were nearly significant (P ¼ 0.049-0.054) independent predictors of sudden death ( Table 6 ). Patients with BMIPP score .16 had significantly lower event-free rates than did those without even though abnormal Q-wave and/or increased .2.38 mg/mL were present ( Figure 3) . Furthermore, compared with the combined use of CRP and abnormal Q-wave, the addition of continuous BMIPP data improved the predictive values assessed by ROC -AUC from 0.712 to 0.812 or more ( Figure 4 ). Table 7 and Figure 5 show statics and incremental performance of prediction models using CRP . Haemodialysis duration prior to this study, years 6.5 + 7.3 (n ¼ 677) 6.9 + 6.4 (n ¼ 20)
Demonstration of two cases with sudden death events Figure 6 shows typical BMIPP images of two cases with sudden death events: a 68-year-old man had multiple defects at the anterior, lateral, and infero-apical walls with a BMIPP score of 22 and increased CRP of 6.47 mg/dL ( Figure 6 , upper panel) and a 67-year-old man also had large defects at the apex, inferior wall, and posterior septum with a BMIPP score of 17 without other abnormalities ( Figure 6 , lower panel).
Discussion
This B-SAFE sub-study demonstrated that increased CRP , electrocardiographic Q-wave, and impaired myocardial BMIPP uptake are Tables 2 and 3 . independently and incrementally related to sudden death in haemodialysis patients. The presented findings provide pathophysiological insights into sudden death mechanisms and, further, indicate a possible improvement in non-invasive risk-stratification by using CRP, electrocardiogram and myocardial fatty acid metabolism assessment using 123 I-BMIPP.
Risk assessment by CRP and electrocardiographic Q-wave
An elevated CRP level is a well-known established biomarker of systemic inflammation due to an atherosclerotic process and cardiovascular risks. 11 Because of the limited number of the samples measured in 386 (57%) of 677 patients, our previous data 9 failed to show the detailed analysis. Nevertheless, this study revealed that CRP can be one of potent determinants of sudden cardiac death and that CRP level of more than 2.38 mg/mL can be a threshold for identifying a high-risk category for sudden death in haemodialysis Abbreviations: see Tables 3 -5. patients. No other conventional coronary risks such as hypertension, diabetes mellitus, or low-density lipoprotein cholesterol were selected as significant predictors. Thus, these findings not only extend clinical values of increased CRP from atherogenic implications to sudden death risk assessment and also strongly support the inflammatory hypothesis of atherothrombosis, which is persistently accelerated during progression of kidney dysfunction or due to haemodialysis procedures, resulting in unexpected cardiovascular death. Among overall electrocardiographic abnormalities, including ST-segment abnormality and left bundle branch block, electrocardiographic Q-wave appearance was identified as a significant predictor of sudden death in haemodialysis patients in this study. Because of no angiographic or other data available, the mechanisms behind abnormal Q-wave appearance, a sufficient deficit of positive depolarization forces, was not clarified in this study. The B-SAFE study did not enroll patients who had clinically overt myocardial infarction or any specific myocardial disorders at entry. 9, 10 Besides subclinical ischaemic myocardial injury or normal variant Q-waves, as so-called 'pseudo-infarct patterns', there are several other possibilities to which pathologic Q-wave can be ascribed in haemodialysis patients; poor R-wave progression, left ventricular hypertrophy due to hypertension or calcified valvular diseases, altered left ventricular conduction, right ventricular overload, hyperkalaemia, and primary or non-ischaemic cardiomyopathies such as uraemic cardiomyopathy and cardiac amyloidosis. Definite exclusion of these pathological conditions, however, may have been difficult to prove. Despite the limited analysis using 228 (33.7%) patients in this study, the B-SAFE study is likely to have enrolled patients who had relatively preserved LVEF with the mean value of nearly 65% and LVEF was not identified as a significant determinant of sudden death. LVEF is established as a clinical marker for prognosis assessment and ICD indication in patients with prior myocardial infarction. It, however, is recently well recognized that heart failure patients with preserved LVEF do not necessarily have better prognosis compared as well as patients with reduced LVEF. 12 Therefore, the present results may support the possibility that LVEF is not a potent prognostic marker in some specific population of patients undergoing haemodialysis. Although increased CRP and Q-wave appearance are likely to be independently involved in sudden death development, the interactive correlations have not been fully elucidated. Nevertheless, it can be speculated that latent myocardial injury that developed during a systemically accelerated atherosclerotic process leads to sudden death, explaining their synergistic prognostic values in haemodialysis patients.
Risk assessment using cardiac fatty acid metabolism imaging
This study showed the ability of myocardial fatty acid metabolism assessment by 123 I-BMIPP to identify haemodialysis patients at an increased risk for sudden death. The prognostic values of myocardial 123 I-BMIPP activity have been shown in haemodialysis patients without known coronary artery disease preliminarily 8 as well as in patients who have stable coronary artery disease or who recovered from acute coronary syndrome. 13 -17 Myocardial fatty acid metabolism is impaired by an acute ischaemic event or inducible ischaemia. 18, 19 Because of the vulnerable nature of beta-oxidation of fatty acids to ischaemia, post-ischaemic impairment of fatty acid metabolism in viable myocardium is observed as a perfusionmetabolism mismatch (i.e. greater BMIPP defect relative to perfusion defect) or an ischaemic memory for several weeks to months. 17, 19, 20 Thus, myocardial 123 I-BMIPP imaging can depict the viable but ischaemic burden or infarct-related risk area in patients with coronary artery disease. 17, 21 The mechanisms behind sudden death in patients with increased BMIPP defect, however, is not clarified in this study but can be speculated to be arrhythmia-related. Cardiac BMIPP defect not only simply indicates impairment of ATP-producing system, fatty acid metabolism, but also strongly suggest subsequent alterations such as accumulation of fatty acid Abbreviations: see Table 5 . intermediates, in particular acyl-CoA, and depletion of the CoA intra-mitochondrial pool in the myocardium. 22 The arrhythmogenecity of the fatty acid intermediate has been shown by a number of investigations in various sorts of disorders. By considering advanced atherosclerotic conditions and the presented results in haemodialysis patients with one or more coronary risks, myocardial ischaemia is most likely to be responsible for impairment of fatty acid metabolism represented by cardiac BMIPP defect, hence developing lethal ventricular arrhythmias and sudden death. Previous studies using patients with stable coronary artery disease 14, 15, 23 showed that nearly 25% segment abnormality or score 4 in a 20-left ventricular segment model is related to cardiac events. The prior B-SAFE study, 9 therefore, used the cut-off for the risk assessment. Because of differences in clinical backgrounds, imaging techniques such as myocardial perfusion imaging, and endpoints such as soft vs. hard cardiac events, all-cause mortality, or sudden cardiac death among studies; however, the presented study tries not only to clarify the threshold value used in the previous study, but also to originally research whether there is a more optimal BMIPP cut-off for the assessment of sudden death risk. The presented results clearly showed that the BMIPP cut-off of 16 was more optimal than that of four or others for sudden death prediction. Although it is difficult to explain reasons for the difference in the cut-off value between the previous and presented studies, these findings suggest important clinical implications for the riskstratification in haemodialysis patients. While cardiac BMIPP score 4 possibly functions as a minimal abnormality responsible for overall cardiac death, a larger risk area defined as a BMIPP score of 16 or more is related more specifically to sudden cardiac death rather than other modes of cardiac death in haemodialysis patients, probably due to a large volume of arrhythmogenic substrate and/or extensive and advanced coronary lesions, all of which lead to sudden death. More clinically, patients with a large BMIPP defect area are very likely to need and, therefore can benefit from, aggressive prophylactic strategy for sudden death prevention using ICD. Despite the limited number of cardiac death for further analysis in this study, there may be different thresholds of BMIPP score for each mode of cardiac death such as death due to pump failure, acute myocardial infarction and lethal ventricular arrhythmias.
Clinical implications
Stress cardiac imaging has been used for the assessment of myocardial ischaemia and cardiovascular risks in patients with end-stage CKD as well as in patients with known or suspected coronary artery disease. Resting myocardial perfusion imaging and late enhancement cardiac magnetic resonance imaging (MRI) are utilized for infarct imaging. There, however, are few data available in these modalities on the risk-stratification and prediction of sudden cardiac death risk in haemodialysis patients. It is of great importance to identify viable myocardium at risk area which could lead to future lethal events and therefore can be a target of therapeutic intervention. This study was not designed to compare BMIPP imaging with other imaging modalities. Nevertheless, several advantages of a cardiac BMIPP imaging technique can be offered in comparison with other methods. Cardiac BMIPP imaging can identify ischaemia-related myocardial injury, including not only infarcted or necrotic myocardium, but also viable ischaemic myocardium or post-ischaemic stunned myocardium, without a stress protocol or without contrast medium as used in cardiac computed tomography or MRI. In addition to the difficulty in keeping arm sites for blood pressure monitoring and tracer injection due to an arteriovenous shunt for haemodialysis, an exercise-stress test sometimes cannot be done appropriately because of muscle weakness, fragility, and/or complicated peripheral artery disease, and a pharmacological approach also cannot necessarily be done safely when hypotension, bradyarrhythmias, and/or obstructive lung disease are present in haemodialysis patients. Finally, easy access, feasibility, cost-effectiveness, and non-invasivity (no adverse effects of contrast medium) should be also considered for the section of imaging tools in haemodialysis patients. Thus, compared with other imaging techniques, the imaging protocol using 123 I-BMIPP is simpler and safer because a resting, single scan with a semi-quantitative visual or automated scoring analysis is used. 23 The present study clearly demonstrated that, in addition to each prognostic significance, CRP, electrocardiographic Q-wave, and cardiac fatty acid metabolism assessment by 123 
Limitations
This study showed that 20 (16%) of 125 lethal outcomes among 677 patients were sudden death. The United States Renal Data System (USRDS) surveillance recently reported that sudden cardiac death accounted for 24.3% of death in patients undergoing dialysis treatment in 2009-11. 6 The small number of sudden death is one of major limitations of this study. There, however, are several possible explanations for that. The report from the Japanese Society of Dialysis Therapy in 2014 (http://docs.jsdt.or.jp/overview/) says that Japanese haemodialysis patients have a low annual death rate (9.8%) which is nearly half of that in the USA (the USRDS report). The B-SAFE study did not included patients who had overt cardiovascular diseases, including coronary artery disease. In addition, causes of death were identified precisely in the remaining 105 patients (86%) who had lethal outcomes because of close cooperation by cardiologists and nephrologists in this prospective study. Nevertheless, a further large-scale study focusing on sudden cardiac death is needed to extrapolate the presented results to more general population. The primary causes of end-stage renal dysfunction which might have affected clinical outcomes were no clarified in this study, although diabetes mellitus was observed in 253 (37.4%) patients and hypertension was present in 595 (87.9%) patients. These underlying diseases were not selected as a prognostic determinant in this study. The B-SAFE database had no sufficient data on cardiac function, coronary angiogram, or potassium levels before and after the haemodialysis procedure. LVEF is one of potential determinants of lethal cardiac outcomes and also available for selecting candidates for ICD therapy to prevent sudden arrhythmic death particularly in patients with prior myocardial infarction. LVEF was not selected as a potent prognostic marker in this study. This is probably because the number of LVEF data available was limited, because this study excluded patients who had definitive cardiac disorders requiring any specific treatment such as severe valvular diseases, idiopathic cardiomyopathy, coronary artery disease, or myocardial infarction, because patients requiring ICD and/or CRT were not included and finally because the mean LVEF measured in 228 patients was well preserved as 64.8 + 10.9%. Further clinical investigation using appropriate cardiac functional information, however, is needed to reveal more detailed mechanisms of sudden death in haemodialysis patients with end-stage CKD.
Finally, the B-SAFE study is a prospective observational but not interventional study. Further study should lead to the establishment of a prophylactic management strategy such as administration of anti-inflammatory agents, anti-arrhythmic device therapy, or coronary interventions in patients at an increased risk for sudden death.
Conclusions
Increase CRP, electrocardiographic Q-wave, and impaired myocardial fatty acid metabolism assessed by 123 I-BMIPP are closely related to sudden death rate, and the combined information improves the identification of haemodialysis patients at an increased risk for sudden death. The non-invasive diagnostic strategy presented here might contribute to the establishment of appropriate prophylactic management for end-stage CKD or haemodialysis patients who can most effectively benefit from a prophylactic treatment against sudden death.
